Population pharmacokinetics of meropenem in burn patients

Journal of Antimicrobial Chemotherapy

Volumn 65, Issue 11, 2010, Pages 2428-2435

  Doh, Kichan ^a   Woo, Heungjeong ^b   Hur, Jun ^b   Yim, Haejun ^b   Kim, Jimyon ^a   Chae, Hongseok ^a   Han, Seunghoon ^a   Yim, Dong Seok ^a  

^a The Catholic University of Korea   (South Korea)

^b Hallym University Medical Center   (South Korea)

Author keywords

Monte Carlo simulation; NONMEM; PK PD modelling; Resistance

Indexed keywords

CREATININE; MEROPENEM;

ADULT; AGED; ARTICLE; BODY SURFACE; BURN INFECTION; BURN PATIENT; CREATININE CLEARANCE; DISTRIBUTION VOLUME; DRUG DISTRIBUTION; DRUG DOSE REGIMEN; EDEMA; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MINIMUM INHIBITORY CONCENTRATION; MODEL; PSEUDOMONAS AERUGINOSA; SIMULATION;

ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; BURNS; FEMALE; HUMANS; KOREA; MALE; METABOLIC CLEARANCE RATE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; PSEUDOMONAS AERUGINOSA; THIENAMYCINS;

EID: 77957869169     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkq317     Document Type: Article

References (23)

1. Weinbren MJ. Pharmacokinetics of antibiotics in burn patients. J Antimicrob Chemother 1999; 44: 319-27.
2. Fry DE. The importance of antibiotic pharmacokinetics in critical illness. Am J Surg 1996; 172: 20-5S.
3. Mouton JW, van den Anker JN. Meropenem clinical pharmacokinetics. Clin Pharmacokinet 1995; 28: 275-86.
4. Jaehde U, Sorgel F. Clinical pharmacokinetics in patients with burns. Clin Pharmacokinet 1995; 29: 15-28.
5. Cockcroft D, Gault M. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16: 31-41.
6. Lindbom L, Pihlgren P, Jonsson N. PsN-Toolkit-a collection of computer intensive statistical methods for non-linear mixed effect modeling using NONMEM. Comput Methods Programs Biomed 2005; 79: 241-57.
7. Song W, Woo H-J, Kang H et al. Comparative in vitro activity of imipenem, panipenem, and meropenem against Pseudomonas aeruginosa and Acinetobacter baumannii isolates. J Korea Soc Chemother 2002; 20: 225-32.
8. Turner PJ. Meropenem and imipenem activity against Pseudomonas aeruginosa isolates from the MYSTIC Program. Diagn Microbiol Infect Dis 2006; 56: 341-4.
9. Drugs@FDA Database. http://www.accessdata.fda.gov/drugsatfda_docs/label/2008/050706s022lbl.pdf (1 June 2010, date last accessed).
10. Drusano G. Prevention of resistance: a goal for dose selection for antimicrobial agents. Clin Infect Dis 2003; 36: 42-50.
11. Lomaestro B, Drusano G. Pharmacodynamic evaluation of extending the administration time of meropenem using a Monte Carlo simulation. Antimicrob Agents Chemother 2005; 49: 461-3.
12. Li C, Kuti JL, Nightingale CH et al. Drugs Population pharmacokinetic analysis and dosing regimen optimization of meropenem in adult patients. J Clin Pharmacol 2006; 46: 1171-8.
13. Isla A, Rodriguez-Gascon A, Troconiz IF et al. Drugs Population pharmacokinetics of meropenem in critically ill patients undergoing continuous renal replacement therapy. Clin Pharmacokinet 2008; 47: 173-80.
14. Kuti JL, Maglio D, Nightingale CH et al. Drugs Economic benefit of a meropenem dosage strategy based on pharmacodynamic concepts. Am J Health Syst Pharm 2003; 60: 565-8.
15. Lee D-G, Choi S-M, Shin W-S et al. Drugs Population pharmacokinetics of meropenem in febrile neutropenic patients in Korea. Int J Antimicrob Agents 2006; 28: 333-9.
16. Blanchet B, Jullien V, Vinsonneau C et al. Drugs Influence of burns on pharmacokinetics and pharmacodynamics of drugs used in the care of burn patients. Clin Pharmacokinet 2008; 47: 635-54.
17. Dailly E, Pannier M, Jolliet P et al. Drugs Population pharmacokinetics of ceftazidime in burn patients. Br J Clin Pharmacol 2003; 56: 629-34.
18. Glew RH, Moellering JR RC, Burke JF. Gentamicin dosage in children with extensive burns. J Trauma 1976; 16: 819-23.
19. Walstad R, Aanderud L, Thurmann-Nielsen E. Pharmacokinetics and tissue concentrations of ceftazidime in burn patients. Eur J Clin Pharmacol 1988; 35: 543-9.
20. Zaske DE, Sawchuk RJ, Gerding DN et al. Increased dosage requirements of gentamicin in burn patients. J Trauma 1976; 16: 824.
21. Patel P, Cook S. Stability of meropenem in intravenous solutions. Am J Health Syst Pharm 1997; 54: 412.
22. Jaruratanasirikul S, Sriwiriyajan S. Stability of meropenem in normal saline solution after storage at room temperature. Southeast Asian J Trop Med Public Health 2003; 34: 627-9.
23. Lee H, Kim CK, Lee J et al. Antimicrobial resistance of clinically important bacteria isolated from 12 hospitals in Korea in 2005 and 2006. Korean J Clin Microbiol 2007; 10: 59-69.